Flagship · Bulletin

Macro rationale

Signals genuinely cross. Risk-on side: VIX 15.3 (-15.5% vs its 200d SMA), HY OAS 2.65 in the richest decile, 63% of sectors above their 50d, 2s10s +0.47 and not inverted, QQQ +9.5% vs 200d. Risk-off side: Iran's declared maritime exclusion zone has Brent near $99 (7-week high) with the SPR under 290Mb — a 42-year low — so the single largest inflation variable is a headline away in either direction; the 10y real yield at 2.42% is genuinely restrictive and is the named reason the macro digest tilts biology -3; and the Fed under Warsh is pinned with hike-side dissents rather than cuts. That is NEUTRAL by construction, not by indecision. The active §5.4 escalator is extension (QQQ +9.5% vs 200d), which lifts the cash ceiling to 25% — I am carrying 21.9%, above the base band, on that named escalator plus the working-reserve line at 14%. Capital-flow direction inside the book is unchanged: XLE +13.1pp rel SPY on Hormuz, XBI +2.6pp, ITA -9.8pp — the defense tape is the laggard while the defense appropriation direction (FY27 $1.5T request, House $1.07T bill) is up, which is the CR-timing drag the brief flagged, not a funder reversal. Not one held name's named funder reversed this week: hyperscaler capex, HBM pre-sold capacity, the $176B GEV backlog, the copper deficit, central-bank gold, DoD MACH-TB/aftermarket flow all intact.

Thesis

One ticket: close NVS. Every other name is a verbatim hold at entry weight, delta 0. NVS is the only genuine thesis break in the trigger set. Pelacarsen — the Lp(a) asset that was the largest single pipeline value driver — missed its Phase III cardiovascular endpoint on 2026-09-07 and the stock took -12.5% in a day; unlock path B is active and the briefer verdict is broken at score 51, unchanged from the 51 I opened it at 16 days ago. My stated scale-in gate was two consecutive quarters of >=6% cc growth with core margin >=40%; that gate is now further away, not closer, and I am not going to hold a starter whose only defence is "I knew the score when I bought it." I own the fast reversal: I underwrote a diversified-cash-flow compounder and the pipeline leg I was paying a premium for just failed on a dated, named readout. BEAM took -12.8% on the same session with NO named cause — no hepatotoxicity, no off-target signal, no discounted raise, which are my three explicit kill criteria. BEAM-302 dosing completed and a late-breaking oral was selected. That is a price fact, not a thesis fact; holding. Entry candidates all fail. GFS: the red team is right — sub-WACC returns, ~24% gross margin, permanent mature-node price war from SMIC/Hua Hong, Mubadala overhang. Pass. BNTX: single-asset BNT327 bet into a PD-L1xVEGF class that just took an OS credibility hit. Pass. RGEN: ~70-100x for low-teens growth capped by Danaher/Sartorius in-sourcing its own OEM channel. Pass. BIO: the 7.4x

Reflection

Biology took the only real break: NVS pelacarsen Phase III failed while compute dispersion (MU/TSM/ASML/AVGO all up 2-4% on the same tape) again showed zero funder reversals.

Tenth straight wake fired on a price move, but this one finally contained a genuine dated event — a failed Phase III — rather than volatility. Useful contrast: NVS and BEAM both crashed ~13% the same session; only one had a named cause, and that is the whole test. I am also updating on my own starter discipline: I opened two sub-60 biology names 16 days ago and am closing one on its first hard datapoint. That is not churn, but it does say my entry bar for a sub-60 pharma on 'diversified cash flow' was really an implicit pipeline bet I did not price. Foundation remains un-openable: zero dossier

Positions (16)

• MUMicron Technologycompute

  hold4.02%87
  flow acceleratingconf

  Funder

  Only US-domiciled leading-edge DRAM/HBM franchise: 84.6% gross margin, FCF positive, and after two decades of cycle abuse a three-player HBM oligopoly that is finally capacity-disciplined and pre-sold. Management has held capex discipline through the ramp rather than buying share. Named flow: ~16 multi-year Strategic Customer Agreements worth ~$100B of contracted HBM, the Anthropic multi-year supp

  Unwind

  Erosion of the SCA contract book or customer deposits being returned; HBM oversupply as 2027 capacity lands; CXMT converting its ~11% DRAM share into leading-edge supply; or gross margin rolling back under 40% as the cycle turns.

  Catalyst

  FQ4 earnings and FY27 HBM allocation commentary (late Sept) — the read on whether 2027 capacity is still pre-sold.

  Scenarios · 12mo targets

  $1,250.00 base

  $1,600.00 bull — HBM4 allocation holds into 2027, SCA book extends, and memory stays sold out — DRAM pricing power persists through a second year.

  $700.00 bear — 2027 HBM capacity lands into a digesting hyperscaler capex line; pricing rolls and the market re-rates MU back to a cyclical multiple.

• TSMTaiwan Semiconductor Manufacturingcompute

  hold6.07%87
  flow acceleratingconf

  Funder

  Effective foundry monopoly at <=3nm — every meaningful AI accelerator routes through it. >50% gross margin, prodigious FCF, famously disciplined capex, ~73% foundry and ~90% advanced-node share, and a management culture that has never chased a customer at a loss. Named flow: CHIPS $6.6B Arizona disbursement locking US capacity, plus the hyperscaler capex line Goldman sizes at $920B-$1.4T for 2027

  Unwind

  Gross margin sustained <50% for two consecutive quarters; a rival closing the leading-edge yield gap; a Taiwan-strait event Arizona capacity cannot offset; or CHIPS-amendment/export-control action removing a material share of advanced-node demand.

  Catalyst

  Q3 earnings and 2027 capex guide (mid-October) plus monthly revenue prints.

  Scenarios · 12mo targets

  $520.00 base

  $640.00 bull — 2nm ramp prices above N3, CoWoS capacity doubles into sold-out demand, and 2027 capex guidance confirms the $1T+ AI silicon line.

  $340.00 bear — A Taiwan-strait escalation or a China export-control tightening that Arizona capacity cannot offset, plus advanced-node digestion compressing margin below 50%.

• NVDANVIDIAcompute

  hold3.76%74
  flow steadyconf

  Funder

  AI-accelerator franchise with the CUDA software moat — 75% gross margin, fortress balance sheet, and developer lock-in no ASIC rival has replicated in a decade. Named flow: ~$279B of disclosed supply commitments (doubled YoY), Blackwell/Rubin anchored on MSFT/AMZN/GOOGL/META 2026 capex budgets and the Stargate JV. Insider selling ($6.3B net over 5yr) is a governance annoyance, not a demand signal

  Unwind

  Data-center revenue YoY <20% for two consecutive quarters; gross margin breaking below the guided 71-72% floor because memory cost cannot be passed through; a named hyperscaler moving a majority of training to in-house silicon; or a compute export-control regime removing China plus a second major geography.

  Catalyst

  Q3 FY27 earnings in November — data-center growth rate and the 71-72% gross-margin floor.

  Scenarios · 12mo targets

  $285.00 base

  $360.00 bull — Rubin ramps on schedule, inference share holds above 70%, and memory cost is passed through with the guided margin floor defended.

  $170.00 bear — ASIC in-sourcing at two named hyperscalers plus HBM cost inflation breaks the margin floor while growth decelerates under 20%.

• ASMLASML Holdingcompute

  hold3.08%64
  flow steadyconf

  Funder

  EUV / High-NA monopoly — the single most irreplaceable tool in advanced semis, with no commercial-scale alternative at 2nm, a multi-year backlog, ~50% gross margin and an installed-base service annuity that keeps earning between order cycles. Named flow: the TSMC/Samsung/Intel 2025-27 EUV orderbook, Norway GPFG holding with Coatue/Third Point adding, and TSMC's 2nm ramp which cannot happen without

  Unwind

  Book-to-bill <0.7 for three consecutive quarters; a Dutch/US export-control tightening removing a material share of the orderbook; or a credible non-EUV patterning path at 2nm.

  Catalyst

  Q3 results 14 October — bookings and the 2027 High-NA shipment schedule.

  Scenarios · 12mo targets

  $2,050.00 base

  $2,500.00 bull — 2nm High-NA orders convert on schedule and 2027 bookings re-accelerate as logic and memory capex overlap.

  $1,300.00 bear — Dutch/US controls widen, China service revenue is stripped, and bookings stay under 0.8 for three quarters.

• AVGOBroadcomcompute

  hold3.04%63
  flow steadyconf

  Funder

  Custom-silicon ASIC leader (~70% share) plus the VMware infrastructure-software lock-in — 69.5% gross margin, huge FCF, $7B+ annual buyback, a serial dividend grower, and Hock Tan's capital-allocation record across a decade of integrations. Named flow: Google TPU multi-generation, Meta MTIA, and the Anthropic ~3.5GW ASIC program; AI silicon grew 221% YoY to roughly a $16.7B quarterly run-rate. The

  Unwind

  AI custom-chip revenue stalling below a ~$25B annual run-rate; full hyperscaler in-sourcing displacing the ASIC design franchise across multiple named accounts; or the buyback being cut to fund leverage.

  Catalyst

  Q1 FY27 results in December — whether the AI run-rate re-accelerates past the guided level.

  Scenarios · 12mo targets

  $450.00 base

  $560.00 bull — Anthropic and a fourth named hyperscaler ASIC program convert, pushing AI silicon past a $35B annual run-rate with VMware margin intact.

  $270.00 bear — A named hyperscaler pulls its ASIC program in-house, AI silicon stalls near $25B, and the software attach rate disappoints.

• ANETArista Networkscompute

  hold2.71%65
  flow steadyconf

  Funder

  Durable hyperscaler-networking franchise and a consistent share-gainer since 2004 — 62.9% gross margin, ~45% GAAP operating margin, zero debt, and the single-image EOS software moat that makes rip-and-replace expensive. Ullal's capital discipline is a two-decade record. Named flow: Microsoft and Meta named as largest customers funding record $3B quarterly revenue; Zacks #1 with a 12.7% consensus e

  Unwind

  Microsoft+Meta combined concentration >50% with revenue decelerating; Spectrum-X or whitebox displacing EOS in a NAMED hyperscaler footprint; or gross margin breaking below 60% on price competition.

  Catalyst

  Q3 earnings in late October — 2027 AI-networking revenue target and customer concentration disclosure.

  Scenarios · 12mo targets

  $235.00 base

  $300.00 bull — 800G AI back-end wins broaden beyond MSFT/META and the 2027 AI networking target is raised with margins held above 45%.

  $140.00 bear — Spectrum-X takes a named hyperscaler back-end footprint and revenue decelerates while a 45x multiple compresses.

• GEVGE Vernovaenergy

  hold4.92%61
  flow acceleratingconf

  Funder

  Gas-turbine and grid franchise with genuine pricing power — heavy-duty turbines effectively sold out through 2030, 10-20% price realization on new orders, and an installed-base service annuity that compounds for decades after the unit ships. Post-spin management has repaired margin and FCF fast. Named flow: $176B backlog, Norway GPFG added post-spin, Oracle/Alphabet datacenter capex pull-through,

  Unwind

  Gas-turbine backlog cancellation or a named hyperscaler power-capex cut; wind-segment losses widening enough to consume gas-segment profit; or the order book ceasing to price at 10-20% realization.

  Catalyst

  Q3 earnings in late October — backlog cadence and gas-segment margin.

  Scenarios · 12mo targets

  $1,150.00 base

  $1,400.00 bull — Backlog pushes past $200B, wind losses turn, and datacenter behind-the-meter orders convert into the 2029-30 slot book at premium pricing.

  $700.00 bear — A hyperscaler power-capex pause defers turbine slots and widening wind losses eat the gas margin recovery.

• SCCOSouthern Copperenergy

  hold8.30%67
  flow acceleratingconf

  Funder

  Tail-risk hedge slot (§5.3): lowest-cost major copper producer with the industry's largest reserve base, 67.6% gross margin, FCF positive with a large dividend, and Grupo Mexico control enforcing capital discipline through the cycle — a 30-year asset life, not a project story. Named flow: copper at an all-time high with a ~320kt 2026 deficit, the $20.5B investment plan with $10.3B earmarked for Ti

  Unwind

  Copper price collapse breaking the deficit thesis; Tia Maria / Los Chancas permitting reversal; a dividend cut signalling balance-sheet stress; or a Peruvian/Mexican fiscal or royalty regime change that expropriates the cost advantage.

  Catalyst

  Q3 results and the Tia Maria construction milestone; any Peruvian permitting decision.

  Scenarios · 12mo targets

  $245.00 base

  $300.00 bull — The copper deficit widens as grid and datacenter demand compounds while Tia Maria adds low-cost tonnes — cash returns step up.

  $150.00 bear — A China-led industrial slowdown breaks the deficit and Peruvian permitting reverses, stranding the growth capex.

• NEMNewmont Corporationenergy

  hold5.47%83
  flow steadyconf

  Funder

  Tail-risk equity hedge (§5.3): largest gold producer with tier-1 long-life assets, strong post-Newcrest FCF and dividend, and visibly improving cost discipline after the divestiture program. Named flow: central-bank gold accumulation continuing, the $1.95B Barrick Nevada JV settlement removing a decade-old operational overhang, and a 2.42% real yield with the SPR at a 42-year low and Brent near $9

  Unwind

  Cost overruns or mine disappointments breaking FCF and the dividend; durable disinflation plus a real-rate surge removing the stagflation-hedge rationale; or a value-destroying acquisition undoing the divestiture discipline.

  Catalyst

  Q3 results — AISC trend and whether the 13% YoY production decline reverses; Barrick JV settlement cash receipt.

  Scenarios · 12mo targets

  $150.00 base

  $190.00 bull — Hormuz escalation plus sticky 3%+ headline CPI keeps the central-bank gold bid while AISC falls and the Barrick cash funds buybacks.

  $95.00 bear — Durable disinflation lets the Fed cut, real yields fall out of gold's favour, and the 13% production decline persists into cost overruns.

• KTOSKratos Defensedefense

  hold11.41%64
  flow steadyconf

  Funder

  Scarce non-prime supplier of attritable airframes (XQ-58A Valkyrie), hypersonics and turbine engines, with a decade of embedded program positions the primes cannot easily displace and vertical propulsion capability almost no peer owns. Named flow: DoD MACH-TB 2.0 $1.45B IDIQ ceiling, Project Helios $68.3M, USMC Valkyrie mods, $55M+ of fresh awards, and the FY27 $1.5T defense request with a $1.07T

  Unwind

  Backlog or contract cancellations; margin failing to inflect through the drone ramp with FCF staying negative through FY2027; a DoD unmanned-systems funding cut in enacted appropriations; or a MACH-TB task-order share loss to Anduril/Castelion.

  Catalyst

  FY27 appropriations / CR resolution (current deadline December 4) and Q3 earnings — first FCF inflection evidence.

  Scenarios · 12mo targets

  $65.00 base

  $85.00 bull — Enacted FY27 appropriations fund the unmanned line, the drone ramp inflects margin, and FCF turns positive on the raised guidance.

  $34.00 bear — A long CR defers new starts, FCF stays negative through FY27, and a MACH-TB task-order loss to a non-traditional rival breaks the scale thesis.

• HEIHEICOdefense

  hold10.23%68
  flow steadyconf

  Funder

  Defense/aero aftermarket compounder and a textbook 20-30 year franchise — the Mendelson family has owned and run it since 1957, compounding FCF above 20% through disciplined tuck-in acquisitions funded from cash flow, with FAA-PMA parts approvals as the moat. 41.1% gross margin, FCF positive. Named flow: NDAA mandatory funding plus the commercial-aerospace MRO cycle; Q2 record net income +49% on s

  Unwind

  Organic growth decelerating below 6% WITH margin compression; a value-destroying large acquisition breaking the tuck-in discipline; a Mendelson management succession failure; or the 54x forward multiple persisting INTO decelerating growth (the clause requires both).

  Catalyst

  Q3 earnings in late August/November cycle — FSG organic growth rate and acquisition cadence.

  Scenarios · 12mo targets

  $370.00 base

  $440.00 bull — MRO cycle stays tight, FSG organic growth holds double digits, and the tuck-in machine deploys $1B+ at accretive multiples.

  $230.00 bear — A commercial-aero air-traffic slowdown decelerates FSG organic growth below 6% and a 54x multiple compresses hard toward the sector.

• LLYEli Lillybiology

  hold3.61%74
  flow steadyconf

  Funder

  Premier pharma compounder — the tirzepatide franchise on 85.8% gross margin plus a manufacturing moat from the $27B capacity build rivals cannot replicate quickly, run by a team with a genuine record of reinvesting into the next franchise rather than financial engineering. Named flow: Mounjaro/Zepbound $27.6B H1 2026 sales, orforglipron (Foundayo) approved April 2026 opening the oral channel, reta

  Unwind

  Tirzepatide US script share falling >5pts to Novo over two quarters; retatrutide Phase 3 disappointing on safety or durability; IRA/MFP negotiation reaching the incretin class at a price that breaks the margin; or the $27B capacity build being written down.

  Catalyst

  Retatrutide Phase 3 readout and Q3 earnings — orforglipron launch trajectory and MFP pricing terms.

  Scenarios · 12mo targets

  $1,350.00 base

  $1,650.00 bull — Retatrutide Phase 3 confirms best-in-class durability and orforglipron opens the oral market without cannibalising injectable pricing.

  $850.00 bear — MFP negotiation reaches the incretin class, Novo/Amgen orals compress price, and script share slips more than 5pts.

• VRTXVertex Pharmaceuticalsbiology

  hold3.00%82
  flow steadyconf

  Funder

  Durable biology compounder: the cystic-fibrosis monopoly (Trikafta/Alyftrek) is a self-funding cash engine on 85.3% gross margin with patent protection into the late 2030s and a fortress net-cash balance sheet, so it never depends on the capital markets the 2.42% real yield is punishing. Named flow: FY2026 revenue guidance raised to $13.10-13.20B, Casgevy sales +151% YoY across 12+ jurisdictions w

  Unwind

  The CF franchise eroding faster than non-CF revenue can replace it; the Crinetics integration destroying value; a suzetrigine commercial failure removing the diversification leg; or net cash being spent down on a value-destroying deal.

  Catalyst

  Q3 earnings — suzetrigine script trajectory and Casgevy reimbursement conversions.

  Scenarios · 12mo targets

  $620.00 base

  $750.00 bull — Suzetrigine converts into a real non-opioid pain franchise and Casgevy reimbursement broadens — non-CF revenue finally de-risks the concentration.

  $420.00 bear — Suzetrigine launch stalls on payer access, Crinetics dilutes returns, and the market re-rates VRTX as a single-asset CF annuity.

• ARGXargenxbiology

  hold2.95%71
  flow steadyconf

  Funder

  The Vyvgart/Vyvgart Hytrulo (efgartigimod) FcRn autoimmune franchise: first-mover platform with a decade of indication runway, commercial-stage, high-margin and net cash, so it self-funds through a restrictive-rate regime. Named flow: FDA expanded gMG approval to all serotypes including seronegative, CIDP label conversion running through payer channels, Sanofi's riliprubart Phase 3 CIDP failure re

  Unwind

  Vyvgart revenue growth stalling; a pipeline indication failure in myositis or Sjogren's; a competitor FcRn entrant (J&J nipocalimab, UCB rozanolixizumab) taking measurable share in gMG or CIDP; or the Forte deal signalling a shift to buying growth.

  Catalyst

  Q3 results — Vyvgart Hytrulo prefilled-syringe conversion rate and myositis/Sjogren's readouts.

  Scenarios · 12mo targets

  $1,200.00 base

  $1,450.00 bull — Myositis and Sjogren's read out positive, Hytrulo self-administration accelerates uptake, and the FcRn franchise compounds unchallenged after Sanofi's exit.

  $750.00 bear — Nipocalimab takes measurable gMG share, a pipeline indication fails, and the 2.42% real yield compresses the multiple on a single-franchise biotech.

• AEISAdvanced Energy Industriescompute

  hold2.60%69
  flow steadyconf

  Funder

  Advanced Energy: 45-year incumbent in precision RF/DC plasma power delivery, designed into etch and deposition process recipes at the major WFE OEMs — requalifying a power supply means requalifying the recipe, which is the switching cost. 41.1% gross margin, FCF positive, net cash. Named flow: the same HBM/WFE capex line MU and ASML ride (Q2 beat with 82.7% EPS growth and raised FY guidance), plus

  Unwind

  Gross margin sustained below 36% on price competition from MKS/Comet/Delta; semiconductor-segment revenue declining two consecutive quarters as the WFE recovery slips; or losing a designed-in socket at a named etch/deposition OEM.

  Catalyst

  Q3 earnings — datacenter book-to-bill and semiconductor-segment order rate.

  Scenarios · 12mo targets

  $350.00 base

  $430.00 bull — WFE recovery broadens with HBM capacity adds while the 800VDC rack platform converts into a second growth leg at OEM scale.

  $200.00 bear — MKS/Comet price competition takes gross margin under 36% and the WFE recovery slips a further two quarters.

• BEAMBeam Therapeutics Inc. Common Stockbiology

  hold1.23%43
  flow steadyconf

  Funder

  Origin platform for base editing (David Liu science, Broad-licensed): single-base correction without double-strand breaks — the most differentiated editing chemistry in the field — with ~$1.2B cash funding BEAM-302 in AATD into 2028, so it is not a hostage to a 2.35% real yield this year. Named flow: Eli Lilly's ~$1.3B acquisition of Verve in 2025 repriced in-vivo LNP editing as a strategic pharma

  Unwind

  preserved out-of-scope

  Catalyst

  preserved

Warnings

• §2 cap re-applied after pillar tilt: KTOS
• §2 cap re-applied after pillar tilt: HEI
• §2 floor: BEAM 0.96% < 1% → closed (no dust)
• §5.4 dry-powder: cash_pct 21.87% above base band top 15% allowed by §3b unfilled-sleeve headroom (+17.5pp, eff top 32.5%)
• cash_band: final cash 23.6% above neutral base band top 15% (escalator active: extension; §3b dry-powder headroom +17.5pp (unfilled opportunistic sleeve → cash)) (§5.4)
• hedge_floor: only 2/3 tail-risk names held (floor escalated: AI-load 30.2% > 30%) — open a gold/oil/diversified-commodity hedge (§5.3); uranium & power-gen do not count
• live_sizing: 1 ticket(s) re-expressed against the executed ledger (§6.6)
• patch_scope: in-scope BEAM omitted from the model's book with no explicit exit (exits[] / zeroed row) — restored at held 1.23% (omission is not a sell, §6.5)
• ledger reconcile: re-emitting unexecuted buys for AEIS

Conviction-lock actions

1. Turn 1ConvictionGuard (§6.5d)

   —
2. Turn 2ConvictionGuard (§6.5d)

   —

Cost breakdown

Per-call cost computed from cost.js pricing constants (Opus 4.7, Sonnet 4.6, Haiku 4.5). Cache-read tokens billed at 10% of input. See Cost & ROI for the rolling 30-day ledger.